Compare CSBR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | INKT |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | 214 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 59.4M |
| IPO Year | 2015 | 2021 |
| Metric | CSBR | INKT |
|---|---|---|
| Price | $4.98 | $12.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | ★ 12.5K | 12.4K |
| Earning Date | 09-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,900,000.00 | N/A |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $8.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.59 | $8.48 |
| 52 Week High | $8.31 | $16.00 |
| Indicator | CSBR | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 63.29 |
| Support Level | $4.71 | $10.84 |
| Resistance Level | $6.31 | $13.40 |
| Average True Range (ATR) | 0.26 | 0.61 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 36.19 | 83.87 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.